Purification and Characterization of Blood Group A-degrading Isoforms of alpha -N-Acetylgalactosaminidase from Ruminococcus torques Strain IX-70*

(Received for publication, December 18, 1996)

Lansing C. Hoskins , Erwin T. Boulding and Göran Larson

From the Department of Medicine, Veterans Affairs Medical Center and Case Western Reserve University, Cleveland, Ohio 44106 and the University Department of Clinical Chemistry and Transfusion Medicine, Sahlgren's Hospital, Gothenburg, Sweden

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
Acknowledgments
REFERENCES


ABSTRACT

To cleave blood group A immunodeterminants from erythrocytes (Hoskins, L. C., Larson, G., and Naff, G. B. (1995) Transfusion 35, 813-821), we purified and characterized alpha -N-acetylgalactosaminidase (EC 3.2.1.49) activity from culture supernatants of the human fecal bacterium Ruminococcus torques strain IX-70. Three isoforms separated during hydrophobic interaction chromatography. Hydroxyapatite chromatography further resolved the most hydrophilic, isoform I, into isoforms IA and IB. The most hydrophobic, isoform III, differed from IA and IB by a more acidic pH optimum, greater heat resistance, greater sensitivity to alkylating agents, and anomalous retardation during gel filtration chromatography. Isoform IB differed from IA and III in N-terminal amino acid sequence and in sensitivity to EDTA inhibition. Each cleaved nonreducing alpha (1right-arrow3)-N-acetylgalactosamine residues from human blood group A and AB mucin glycoproteins, Forssman hapten, and blood group A lacto series glycolipids. The apparent molecular mass of denatured isoform subunits of IA, IB, and III-PII (158, 173, and 201 kDa, respectively) bore no integer relationship to the apparent molecular mass of the native isoforms (265, 417, and 530 kDa), but the latter bore a ratio of 1.96:3.09:3.93 to the weight-average apparent molecular mass of native IA (135 kDa), suggesting that the isoforms are multimers of a 135-kDa sequence. Isoforms IA and III-PII had an identical N-terminal amino acid sequence which showed homologies to the N-terminal sequence of sialidases produced by Bacteroides fragilis SBT3182, another commensal enteric bacterium.


INTRODUCTION

Enzymatic conversion of blood group A or B erythrocytes to universal donor O-like red cells is feasible providing that nonreducing terminal alpha 3-N-acetylgalactosamine (alpha -GalNAc) residues, the major immunodeterminants of blood group A, or alpha 3-galactose residues, the immunodeterminants of blood group B, are cleaved from red cell membrane glycoconjugates by the respective linkage-specific glycosidases (1-10). Lenny and associates (2-4) have demonstrated that blood group B red cells whose B immunodeterminants were removed by coffee bean alpha -galactosidase survive normally in blood group A and O recipients.

Conversion of blood group A erythrocytes to O-like cells has been reported by Aminoff and co-workers (5-7) using alpha -N-acetylgalactosaminidase (alpha -GalNAcase, EC 3.2.1.49)1 purified from culture supernatants of Clostridium perfringens and by Goldstein et al. (8, 9) and Hata et al. (10) using chicken liver alpha -GalNAcase. But C. perfringens strains also produce toxins and other extracellular hydrolases which make purification of a single glycosidase difficult (5, 11, 12), whereas alpha -GalNAcases from nonbacterial sources have acidic pH optima in the range 3.5-4.8 and little or no activity at pH >= 7.0 (liver (10, 13-20), fungi (21, 22), mollusks (23-27), and Ehrlich ascites tumor cells (28)). For these reasons we purified alpha -GalNAcase from the culture supernatants of Ruminococcus torques strain IX-70 (ATCC 35915) and report here on the purification and properties of three of its isoforms.


EXPERIMENTAL PROCEDURES

Materials

Phenyl-SepharoseTM CL-4B, SephacrylTM S-300 HR, and DEAE-SephadexTM A-50 were purchased from Pharmacia Biotech Inc. and hydroxyapatite gel (Bio-Gel HTP) from Bio-Rad. All general chemicals were reagent grade.

Buffers

Enzyme separation buffer (ESB) was 100 mM NaCl containing 20 mM NaKHPO4 buffer, pH 6.0, 1 mM MgCl2, and 0.1 mM Na2EDTA. ESBA was ESB containing 3 mM sodium azide. Enzyme assay buffer (EAB) was ESB containing 0.1% v/v Triton X-100 and with phosphate buffer replaced by 20 mM N-[2-acetamido]-2-aminoethanesulfonic acid buffered at pH 6.0. EABA was EAB containing 3 mM sodium azide. EA buffer used in incubations with glycosphingolipid substrates was ESB modified by containing 7-10 mM sodium deoxycholate and substituting 20 mM Na2HPO4 buffer at pH 6.4 for NaKHPO4 buffer. Pronase buffer was 100 mM NaCl containing 20 mM Tris-HCl buffer, pH 7.8, 5 mM CaCl2, and 3 mM sodium azide.

Substrates

para-Nitrophenyl (pNP)- alpha - and beta -glycopyranosides were purchased from Sigma and Toronto Research Biochemicals, Inc. Toronto, Canada. Hog gastric mucin was purified (29) from a commercial source (Lot 26303, ICN Biochemicals, Cleveland, OH) and contained 1.3 and 2.6 µg/ml minimal hemagglutination inhibiting concentrations (MHIC) of blood group A and H antigen, respectively. Mucin glycoprotein subunits were purified from human small intestinal mucosal scrapings obtained at autopsy from a blood group A secretor and a blood group AB secretor. Homogenates of mucosal scrapings (20% w/v), prepared in 0.15 M NaCl containing 20 mM NaKHPO4 buffer, pH 7.4, and 3 mM sodium azide, were incubated for 48 h at 37 °C with 0.2 M 2-mercaptoethanol (MCE) and then boiled and centrifuged at 16,000 × g. Ethanol was added to the supernatant at 0-2 °C to 60% v/v. The precipitate was dissolved in Pronase buffer and digested sequentially with ribonuclease, deoxyribonuclease, and Pronase at respective concentrations of 0.6 and 12 Kunitz units and 0.4 PUK units/g mucosal wet weight before being again boiled, centrifuged, and reprecipitated with ethanol to 60% v/v. The final precipitate was lyophilized after dissolving in and dialyzing against 1 mM ammonium acetate. The yield of group A subunits is as follows: 11 mg of glycoprotein/g of mucosal wet weight; composition, 41.8% w/v hexoses, 11.3% w/v protein, and 1.3 µg/ml and 42 µg/ml MHIC of A and H antigen, respectively. The yield of group AB subunits is as follows: 5.7 mg of glycoprotein/g of mucosal wet weight; composition, 28.1% w/v hexoses, 12.0% w/v protein, and 0.08 and 0.65 µg/ml MHIC of A and B antigen, respectively, with no detectable H antigen (MHIC >= 333 µg/mg).

Glycolipid Substrates (G.L.)

The glycolipid standards LcOse4Cer, H-5-1 (IV2Fucalpha -LcOse4Cer), Lea-5 (III4Fucalpha -LcOse4Cer), Leb-6 (IV2III4(Fucalpha )2-LcOse4Cer), and the substrates A-6-1 (IV3GalNAcalpha , IV2Fucalpha -LcOse4Cer), A-7-1 (IV3GalNAcalpha ,IV2III4(Fucalpha )2-LcOse4Cer), and GM3 (II3NeuAcalpha -LacCer) were prepared from pooled human meconia of blood groups O and A, respectively (30, 31). Lactosylceramide (LacCer) and Forssman (IV3GalNAcalpha -GbOse4Cer) glycolipids were prepared from dog small intestine (32, 33).

Culture Medium

The anaerobic culture medium was "Medium 75" (29) modified by replacing 3 g/liter of the 15 g/liter Casamino acidsTM (Difco) with 3 g/liter of a pancreatic digest of casein (TrypticaseTM, BBL Microbiology Systems, Cockeysville, MD) and deleting tryptophan and hog gastric mucin supplements.

Methods

Glycosidase activities were measured in samples diluted to ensure that enzyme concentration was rate-limiting using pNP-glycopyranoside substrates in EAB at pH 6.0 and at 37 °C as described previously (34). Sialidase was measured from the rate of cleavage of sialic acid from serum orosomucoid as described (34), and fucosidase was measured by the rate of cleavage of L-fucose from a purified human gastric mucin with a high H antigen titer using fucose dehydrogenase (Boehringer Mannheim) to measure the released fucose (35). One unit of enzyme activity was defined as that amount cleaving 1 µmol of product/min at pH 6.0 and 37 °C.

One mM MgCl2 and 0.1 mM Na2EDTA were included in incubations after we observed that these enhanced and stabilized enzyme activity in crude glycosidase mixtures. 0.1% v/v Triton X-100 enhanced several glycosidase activities by 30-50% in crude preparations and was included in all enzyme assays using pNP-glycoside substrates. We included 1 mg/ml bovine serum albumin in assays of purified alpha -GalNAcase preparations at concentrations <= 1 µg/ml since this improved the coefficient of variation (CV) among replicates from ±40 to ±6%.

Characterization of Substrate Specificities

Cleavage of GalNAc from blood group A and AB mucin glycoprotein subunits by purified enzyme fractions was measured in incubation mixtures containing 2.1 mg of mucin glycoprotein subunits and 1.3 milliunits of enzyme per ml of ESBA. Aliquots were removed at intervals, heated 3 min at 100 °C, and cooled, and ethanol was added to 80% v/v. After 16 h at -20 °C the aliquots were centrifuged. The glycoprotein precipitate was dissolved in 0.1 M NaCl and analyzed for residual hexose using anthrone (36) with D-galactose as standard, and for ABH blood group antigens by hemagglutination inhibition titration (15). The supernatants were flash evaporated to dryness, reconstituted in distilled water, and analyzed for N-acetylhexosamines using GalNAc as standard (37). Results were expressed as nmol of GalNAc released per h/mg of mucin. For further identification of saccharide cleavage products the reconstituted solutions were deionized by passage through AGTM 50W-X4 and AGTM 1-X8 ion exchange resins (Bio-Rad); the eluates were evaporated to dryness and reconstituted in a minimal amount of distilled water. They were applied along with saccharide standards to thin layer chromatography (TLC) plates (HPTLC Silica Gel 60 plates, no. 5641, Merck, Darmstadt, Federal Republic of Germany) which had been presoaked in 0.2 M borate buffer at pH 8.0 before being activated by heating 30 min at 180-200 °C. Chromatograms were developed using n-butanol/pyridine/methanol/H2O (3:3:3:1). The saccharide spots were detected with cupric acetate reagent (38) and by examination under UV light at 365 nm.

Measurement of Glycolipid Substrate Specificities (G.L.)

Enzymatic hydrolysis of glycolipids was performed as described previously (31) at 37 °C in EA buffer, pH 6.4, containing 7-10 mM sodium deoxycholate. Incubation mixtures contained 130-1760 milliunits of isoform and 5-24 µg of glycolipid substrate in a ratio of 7-88 milliunits of enzyme per µg of glycolipid. Aliquots were removed at intervals from 1 to 24 h and desalted on 0.1 g of C18 prepacked Bond Elut7 columns (Analytichem International, Harbor City, CA). For analysis by thin layer chromatography samples and glycolipid, standards were applied to TLC plates (no. 5641, Merck) that were developed with chloroform/methanol/water, 60:35:8 (v/v/v) and stained with anisaldehyde reagent (33).

Analytical Methods

Protein was assayed with the Folin-phenol reagent (39) or with fluorescamine (40) using human serum albumin as standard. Electrical conductivity of eluate fractions during column chromatography was measured on appropriately diluted samples with a conductimeter (Radiometer A/S, Copenhagen) and converted to NaCl or phosphate concentration by reference to conductivity curves of standard solutions containing NaCl or phosphate in ESBA. Polyacrylamide gel electrophoresis (PAGE) under nondenaturing conditions was performed by standard methods (41) using 3% polyacrylamide stacking and 5% running gels at pH 8.3. PAGE under denaturing conditions (SDS-PAGE) was performed at pH 7.0 by a modification (42) of the method of Weber and Osborne (43) and at pH 8.3 by the method of Laemmli (44, 45). Gels were stained for protein with Coomassie Blue or Silver (44) and for carbohydrate with periodic acid-Schiff stain (46). Optical densitometry of gels stained with Coomassie Blue was performed using an optical scanner (model SciScan 5000, U. S. Biochemical Corp.) with image analysis software (Oberlin Scientific Corp. Os-Scan Image Analysis System).

Measurement of Enzyme Properties

Apparent molecular mass of denatured subunits was determined using SDS-PAGE at pH 7.0 by comparing the relative migration rates of enzyme samples with 40-200-kDa protein standards (SDS-PAGE high range standards, Bio-Rad) (42, 43). Apparent molecular mass of the purified native isoforms was determined by comparing their elution volumes with those of protein molecular weight standards (Pharmacia Kit 17-0441-1) during gel filtration in ESBA on a 1.6 × 76-cm column of Sephacryl S-300 calibrated with blue dextran 2000 (Pharmacia) (V0) and 0.4 M NaCl (Vt) by conductivity measurement (47). Apparent molecular mass of the purified native isoforms was also determined by nondenaturing PAGE from Ferguson plots with 4.5-10% gels by a modification (48) of the method of Bryan (49) using nondenatured, high molecular weight protein standards (Sigma MW-ND-500). The weight-average apparent molecular mass (wt-ave, m) of the native isoforms was calculated from optical densitometry scans of 5% PAGE gels using Equation 1:
<UP>wt-ave,</UP> m=<LIM><OP>∑</OP><LL>i<UP>=</UP>1</LL><UL>n</UL></LIM> <UP>OD</UP><SUB>i</SUB>(m<SUB>i</SUB>)÷<LIM><OP>∑</OP><LL>i<UP>=</UP>1</LL><UL>n</UL></LIM> <UP>OD</UP><SUB>i</SUB> (Eq. 1)
where ODi indicates the area under the optical density peak of the ith protein band, mi indicates the molecular mass of the ith protein band, and n indicates the number of protein bands with measured optical density peaks.

Amino acid analysis and N-terminal sequence analysis of isoforms IA, IB, and III-PII were performed by Cheryl Lea Owens in the Molecular Biology Core Laboratory of Case Western Reserve University. For amino acid analysis samples were hydrolyzed in N HCl, and the phenylisothiocyanate derivatives were analyzed (50) using a model 420A Amino Acid Analysis System (Perkin-Elmer). Results were the mean of duplicate analyses. To determine if the observed differences in amino acid content among the three isoforms were due solely to assay variability, we calculated the CV of the amino acid composition of a single peptide standard in 15 assays performed on 3 separate days. The average same day CV among 18 amino acids was ±15.1% (range: 7.6-36.3%), the greatest being with Cys (±36%), Met (±36%), Ile (±23%), and Val (±26%). N-terminal sequence analysis was performed using Edman degradation (51) with a ProciseTM model 494 Protein Sequencer (Perkin-Elmer).

Kinetic Analysis

Km and Vmax were determined from Lineweaver-Burk plots of assays performed at 37 °C in EAB buffered at pH 6.2 using pNP-alpha -GalNAc as substrate.

pH activity was determined over the range 3.0-9.0 in incubation mixtures containing 38 mM citrate-phosphate or Tris-HCl buffer and measuring the final pH of the incubation mixtures after incubation. pH stability was measured by incubating the enzymes in the same buffers for 4 h at 4 °C and then dialyzing them overnight in ESBA at pH 6.0 before assaying. Thermal stability was measured by assaying samples that had been incubated at 50 and 55 °C in ESBA for 0, 30, 60, and 120 min.

Effect of Added Reagents and Ions

Incubations with additives were performed in EAB buffer, pH 6.0, devoid of Triton X-100, magnesium and EDTA. Tests for EDTA inhibition were carried out by first dialyzing the purified enzyme preparations overnight against 0.1 M Na2EDTA buffered at pH 6.0 followed by dialysis against several changes of EAB devoid of Triton X-100, magnesium and EDTA before assaying for residual activity with and without added cations. Incubations with iodoacetamide, N-ethylmaleimide, p-hydroxymercuribenzoate, HgCl2, and CuSO4 were performed at final concentrations of 1 and 10 mM for up to 24 h.

Statistical significance of the differences in amino acid composition and in the effect of ions on the activities of the three isoforms was determined using the Kruskal-Wallace analysis of variance by ranks test (52).

Purification of alpha -GalNAcase

In Step 1, 15-liter batch cultures of R. torques were grown in Medium 75 without glucose that had been prereduced by boiling prior to autoclave sterilization and cooled under a stream of N2. Following inoculation, the culture was stirred continuously at 37 °C until bacterial growth, monitored by optical absorbance at 660 nm, had entered early stationary phase. Then a sterile solution of glucose in anaerobic Medium 75 was added at a rate of 1 g/h until an additional 4 g of glucose/liter of culture had been added. Incubation was continued for an additional 24 h and then the bacterial cells were removed by filtration through a 0.5-µm DuraporeTM filter in a PelliconTM cassette (Millipore Corp. Bedford, MA). The cell-free filtrate was then concentrated 10-fold by ultrafiltration through a Pellicon "PT" cassette filter with a 10-kDa cutoff. All subsequent steps were performed at 4 °C. For Step 2, fractionation was performed with (NH4)2SO4. Solid (NH4)2SO4 was added to the concentrated filtrate to a final concentration of 1.25 M. After standing 16-24 h the small amount of precipitate was removed by centrifugation and discarded. More (NH4)2SO4 was added to a final concentration of 3.5 M with respect to the initial volume. After standing 16-24 h the precipitate was collected by centrifugation at 10,000 × g and dissolved in and dialyzed against ESBA. Step 3 was hydrophobic interaction column chromatography at high ionic strength. Solid NaCl was slowly added to the dialyzed (NH4)2SO4 fraction to a final concentration of 4.0 M, and Triton X-100 was added to a final concentration of 0.1% v/v. We added 0.1% v/v Triton X-100 to remove any lipid and lipophilic impurities as mixed micelles because preliminary studies using Sudan Black as a micellar marker dye showed that Triton X-100 remained tightly bound to phenyl-Sepharose throughout gradient elution. The fraction was then applied to a 2.6 × 87-cm column of phenyl-Sepharose which had been pre-equilibrated with 11 column volumes of ESBA, 4.0 M NaCl. Following sample application the column was eluted at 22 ml/h with ESBA, 4.0 M NaCl until the eluate absorbance at 280 nm returned to base line. The column was then eluted with a two-step decreasing linear ionic strength gradient; the first step consisted of 6.5 column volumes of constantly stirred ESBA, 4.0 M NaCl in a mixing chamber to which an equal volume of ESBA, 2.0 M NaCl was added; the second step followed and consisted of 4 column volumes of ESBA, 2.05 M NaCl in the mixing chamber to which an equal volume of ESBA was added. Elution was completed with 2 column volumes of ESBA. Eluate fractions were assayed for enzymatic activities and for NaCl concentration by conductivity measurement.

alpha -GalNAcase activity eluted in three peaks which were pooled as separate isoforms (Fig. 1, top). Isoform I eluted at 3.2 right-arrow 3.15 M NaCl, isoform II eluted at 2.9 right-arrow 2.8 M NaCl along with the single main beta -galactosidase (beta -gal'ase) peak, and isoform III eluted over the range 1.0 right-arrow 0.12 M NaCl at the end of the elution gradients. Step 4 was chromatography on hydroxyapatite (Fig. 2). Isoform I was applied to a 1.6 × 10-cm column of hydroxyapatite (Bio-Rad HTP) pre-equilibrated in ESBA buffer. Unabsorbed, inactive protein and excess NaCl were removed by eluting the column with ESBA, and then the column was eluted into 10-ml fractions with an increasing phosphate concentration gradient using 30 column volumes of ESBA containing 40 mM NaKHPO4, pH 6.0, buffer in the mixing chamber and 30 column volumes of ESBA containing 200 mM NaKHPO4, pH 6.0, buffer in the reservoir. alpha -GalNAcase eluted in two successive peaks behind a small peak of beta -Galase; these were pooled separately and labeled as isoforms IA and IB, respectively (Fig. 2). Step 5 with isoforms IA and IB (Fig. 3) was gel filtration chromatography, as follows. Peaks IA and IB were further purified by gel filtration over a 1.6 × 76-cm column of Sephacryl S-300 equilibrated in, and eluted with, ESBA. The final active fractions were pooled and concentrated by ultrafiltration on a YM-10 membrane (Amicon Corp., Cambridge, MA). Hydroxyapatite chromatography was performed with isoform III in a similar manner. alpha -GalNAcase in this fraction eluted in a broad peak that partly overlapped with beta -Galase and smaller amounts of beta -N-acetylglucosaminidase (beta -GlcNAcase). alpha -GalNAcase fractions with the least amount of beta -Galase and beta -GlcNAcase were pooled and applied to a 1.6 × 23-cm column of DEAE-Sephadex that had been pre-equilibrated in ESBA. The column was washed with ESBA, and alpha -GalNAcase was eluted with a gradient consisting of 13 column volumes of ESB buffer containing 0.15 M NaCl in the mixing chamber and an equal volume of ESB containing 0.5 M NaCl in the reservoir. Fractions with peak alpha -GalNAcase activity were pooled, applied to a 1.6 × 76-cm column of Sephacryl S-300 pre-equilibrated with ESBA, and eluted with ESBA. alpha -GalNAcase in fraction III differed from alpha -GalNAcase in IA and IB by displaying abnormal elution behavior from Sephacryl S-300 (Fig. 3); whereas half of the activity eluted as a discrete peak near the void volume along with traces of beta -GlcNAc'ase, sialidase, and fucosidase (isoform III-PI), elution of the remainder was retarded because of apparent anomalous interaction with the gel bed; this portion eluted over two bed volumes as a long, slowly declining shoulder of the main peak (isoform III-PII). These were pooled separately and concentrated on a YM-10 membrane.


Fig. 1. Elution of glycosidases of R. torques strain IX-70 during hydrophobic interaction chromatography on phenyl-Sepharose CL-4B. Top, elution of alpha -GalNAcase isoforms I, II, and III. alpha -GalNAcase, bullet ; specific conductivity, triangle . The sharp elution peak above fraction 1100 is an artifact due to a sharp decrease in ionic strength. Bottom, elution of five other glycosidase activities. beta -GlcNAcase, bullet ; beta -GalNAcase, black-triangle; beta -Galase, black-square; alpha -L-fucosidase, black-down-triangle ; endo-alpha -GalNAcase. black-diamond ; specific conductivity, triangle .
[View Larger Version of this Image (39K GIF file)]



Fig. 2. Separation of beta -Galase from alpha -GalNAcase and resolution of alpha -GalNAcase isoform I into isoforms IA and IB during gradient elution column chromatography on hydroxyapatite. The values of beta -Galase activity in the figure are 25-fold greater than the actual values. alpha -GalNAcase, black-square; beta -Galase, bullet ; phosphate concentration, square .
[View Larger Version of this Image (15K GIF file)]



Fig. 3. Composite diagram of the elution patterns of isoforms IA, IB, and III during gel filtration on Sephacryl S-300 showing anomalous elution of isoform III extending over 2.5 column volumes. V0, void volume; Vt, gel bed volume; IA, black-square; IB, bullet ; III, triangle .
[View Larger Version of this Image (12K GIF file)]



RESULTS

Purification of alpha -GalNAcase Isoforms

The key steps were hydrophobic interaction column chromatography on phenyl-Sepharose followed by column chromatography on hydroxyapatite (Table I). alpha -GalNAcase eluted from phenyl-Sepharose in three separate peaks of increasing hydrophobicity, isoforms I, II, and III (Fig. 1, top). The first and most hydrophilic, isoform I, eluted ahead of other glycosidases (Fig. 1, bottom) and comprised 9.1% of the total alpha -GalNAcase activity recovered in this step. Hydroxyapatite chromatography further resolved isoform I into two peaks, IA and IB, respectively, comprising 43 and 56% of the eluted activity (Fig. 2). The second peak, isoform II, eluted with beta -gal'ase. When pooled, this fraction comprised only 3% of total recovered activity and was not investigated further. The third and most hydrophobic peak, isoform III, comprised 48% of total recovered activity and required anion exchange chromatography in addition to hydroxyapatite chromatography to separate it from other glycosidases. It displayed anomalous elution behavior during gel filtration chromatography on Sephacryl S-300; one-half, III-PI, eluted near the column void volume together with small amounts of other glycosidase activities, and the remainder, III-PII, eluted over two column volumes in nearly pure form (Fig. 3). alpha -GalNAcase recoveries in IA, IB, III-PI, and III-PII were 0.7, 1.9, 1.8, and 1.7%, respectively, totaling 6.1% of the initial culture filtrate activity purified 26-121-fold (Table I). They contained traces of other activities that were less than 0.5% of alpha -GalNAcase activity (Table II). None of the alpha -GalNAcase isoforms possessed alpha -galactosidase activity which is present in purified lysosomal alpha -GalNAcase (10, 16-18, 28, 53). Isoforms IA and IB contained no detectable sialidase or H-degrading alpha -fucosidase activity, but III-PII contained small amounts of both that comprised 0.02 and 0.1% of alpha -GalNAcase activity, respectively, and alpha -fucosidase in this fraction co-migrated with alpha -GalNAcase activity during PAGE.

Table I.

Purification of alpha -N-acetylgalactosaminidase from the culture supernatant of R. torques strain IX-70


Step Total unitsa Total protein Specific activity Yield Purification

mg units/mg % -fold
Culture supernatant (30 liters) 5320 9940 0.54 100 1.0
1.25-3.5 M (NH4)2SO4 precipitate 5720 5160 1.11 107 2.0
Phenyl-Sepharose chromatography
  -Isoform I 297 456 0.65 5.6 1.2
  -Isoform III 1560 476 3.3 29 6.1
Hydroxyapatite chromatography
  -Isoform IA 83 1.6 53 1.6 98
  -Isoform IB 108 2.8 39 2.0 72
  -Isoform III 794 114 7.0 14.9 13
DEAE-Cellulose chromatography
  -Isoform III 307 12 25 5.8 46
Gel filtration chromatography
  -Isoform IA 35 0.53 65 0.7 121
  -Isoform IB 103 1.9 55 1.9 102
  -Isoform III
    -Pool I 98 7.0 14 1.8 26
    -Pool II 89 2.4 37 1.7 68

a 1 unit = that amount catalyzing release of 1 µmol of product/min.

Table II.

Glycosidase activities in culture supernatant of R. torques IX-70 and in purified isoforms of alpha -N-acetylgalactosaminidase


Glycosidase Activity, units/mg protein
Culture Isoforms
IA IB III P-II

 alpha -N-Acetylgalactosaminidase 0.54 65 55 37
 beta -N-Acetylglucosaminidase 0.53 0.03 0.07 0.03
 alpha -Galactosidase <0.009 <0.009 <0.009
 beta -Galactosidase 0.70 0.31 0.01 0.01
 alpha -L-Fucosidase 0.68 NDa NDa 0.29
Sialidase 0.04 <0.001 <0.001 0.009
Endo-alpha -GalNAcaseb 0.63 0.16 0.02 0.1

a ND, no decrease in H antigen titer during 5 h of incubation with 8 units of enzyme.
b Assayed using as substrate pNP-O-beta -D-galactosyl-(1right-arrow3)-2-acetamido-2-deoxy-alpha -D-galactopyranoside.

Properties of alpha -GalNAcase Isoforms: Homogeneity and Molecular Size Relationships (Fig. 4, Table III)

On denaturing SDS-PAGE IA and IB were a mixture of two subunit proteins with molecular mass of 158 and 172 kDa. By scanning densitometry IA was comprised of 69% of the 158-kDa band and 31% of the 172-kDa band, and IB was comprised of 97% of the 172-kDa band and 3% of the 158-kDa band. III-PII was a single subunit band at 205 kDa, and III-PI, which contained small amounts of other activities, was comprised of a single band at m = 201 kDa and three other smaller, weakly staining bands. None of the isoform protein bands stained with periodic acid-Schiff stain following SDS-PAGE of 14-50 µg of IA, IB, or III-PII. None of the following pretreatments altered band appearance on SDS-PAGE: incubation at pH 3.9 or at 9.1 immediately prior to electrophoresis at pH 7.0, or heating the samples at 100 °C with SDS and MCE by the method of Laemmli (44, 45), with and without adding 6 M urea to the cooled samples prior to electrophoresis.


Fig. 4. A, SDS-PAGE patterns of denatured isoforms and molecular mass standards (kDa); B, PAGE patterns of native isoforms in 5% polyacrylamide running gels.
[View Larger Version of this Image (44K GIF file)]


Table III.

Apparent molecular mass, m, of isoforms IA, IB, and III, kDa


IA IB III

1. m of protein bands by denaturing SDS-PAGE  <UNL>158</UNL>a  <UNL>173</UNL>a III-PI: 201 III-PII: 205 
172 158
2. m of main protein band by nondenaturing PAGE 117 234 III-PII: 330 
3. Weight-ave. m 135 229 III-PII: 295 
4. m by gel filtration 265 417 III-PII: 530

a Underlined values are those of the dominant protein band.

On nondenaturing PAGE the three native isoforms displayed a single major protein band and several weaker, enzymatically active ones which were most prominent in isoform IA. The weight-average molecular mass of native isoforms IA, IB, and III-PII, determined by scanning densitometry, was 135, 229, and 295 kDa, respectively. The molecular mass determined by gel filtration was 265, 417, and 530 kDa, respectively, with a ratio of 1.00:1.57:2.00. A monomer of 133 kDa would satisfy this size relationship within a 4.3% error if it were present as a dimer, a trimer, and a tetramer in IA, IB, and III-PII. The size of such a monomer is virtually identical to the weight-average molecular mass of native isoform IA (135 kDa).

Amino acid analysis (Table IV) revealed that overall there was no statistically significant difference in the mol % composition of 16 amino acids among the three isoforms, the mean CV being ±19.0% with a range of ±1.9% to ±35%. The variation among six of the amino acids was less than the inherent variation in the assay (CV = ±15.1%, see "Methods"). In isoform IB the mol % composition showed slightly greater differences from IA and III-PII (CV = ±17 and ±19%) than between IA and III-PII (CV = ±15%), but the differences were statistically insignificant.

Table IV.

Amino acid composition of isoforms IA, IB, and III


Amino acid Composition
Coefficient of variation
IA IB III-PII

mol % %
Asp 9.5 14.1 12.1 ±19.2
Glu 9.2 8.9 11.4 ±13.8
Ser 5.4 5.5 5.6 ±1.9
Gly 10.2 9.6 8.2 ±11.1
His 0.9 0.6 1.3 ±35.0
Arg 2.0 1.8 2.1 ±7.3
Thr 9.0 11.6 8.8 ±16.0
Ala 12.3 8.6 14.7 ±25.7
Pro 3.7 4.2 2.4 ±27.3
Tyr 3.0 3.6 2.8 ±13.2
Val 10.9 8.0 7.9 ±19.1
Met 1.4 2.5 1.9 ±29.5
Ile 8.3 5.2 6.0 ±24.9
Leu 8.8 5.6 8.6 ±23.2
Phe 4.1 3.9 2.4 ±26.2
Lys 5.3 6.2 6.4 ±10.2
Mean: ±19.0

N-terminal sequence analysis of the first 20 amino acids (Table V) revealed an identical sequence in isoforms IA and III except that Ala in position 6 of isoform III was present as a minor amino acid in position 6 of isoform IA. A putative N-glycosylation sequence was present in positions 3-5. By contrast, the N-terminal sequence in isoform IB differed completely from that of IA and III. Consistent with the evidence from SDS-PAGE that some IB was present in IA, 13 of 20 minor amino acid peaks encountered during sequencing of IA were identical to those of isoform IB. A BLAST search (54) of the protein data base of the National Center for Biotechnology Information, the National Library of Medicine, revealed homologies in the N-terminal sequence of isoform III with the N-terminal sequence of sialidase isoforms of Bacteroides fragilis SBT3182 (55), another human commensal enteric bacterium. No matches were found with isoform IB in the BLAST search.

Table V.

N-terminal amino acid sequences in isoforms IA, IB, and III

The top row of IA and IB displays the most probable amino acids in the sequence, and the second row displays other amino acids detected at each position, with an X indicating an indeterminate residue. Bold lettering indicates amino acids in positions identical with isoform III whose sequence was unambiguous. The N-terminal sequence of sialidase isoforms of B. fragilis SBT3182 is aligned with those of isoform III to show positions of identity (double dots) and of functionally similar amino acids (single dots).
IA     1                  20
    AENETEVPYGKVTVEQKDNT
    EDTAAAQGQTXEKXSXXVHX
IB     EDTAAEQGQTPEKKSGTVQD
    GVGKTPKKKANXKVVAX XQ
III     AENETAVPYGKVTVEQKDNT
       :: .: . .: ::
B. fragilis sialidase (55) ADXIFVRETRIP ILIERQDN
1      8   12     16  20

Substrate Specificity: Mucin Glycoproteins (Fig. 5)

alpha -GalNAcase activity in IA, IB, and III rapidly cleaved GalNAc from human blood group AB (Fig. 5A) and group A (Fig. 5B) mucin glycoprotein subunits with a decrease in blood group A antigen titer, a rise in H antigen titer, and no change in B antigen titer. TLC of the saccharide cleavage products revealed a single spot corresponding to GalNAc in each digestion mixture.


Fig. 5. Top, decrease in A antigen titer and release of GalNAc from 2.1 mg of blood group AB active human mucin glycoprotein subunits during incubation with 1.3 milliunits of isoforms IA, IB, and III-PII per ml of incubation mixture. No decrease in B antigen titer occurred (not shown). Open symbols, A antigen titer; closed symbols, GalNAc released. IA, squares; IB, circles; III-PII, triangles. Bottom, decrease in A antigen titer, simultaneous increase in H antigen titer, and release of GalNAc during incubation of blood group A active human mucin glycoprotein subunits with 0.6 milliunits of isoform IB/mg of glycoprotein subunits. A antigen titer, open circle ; H antigen titer, square , GalNAc released; bullet .
[View Larger Version of this Image (31K GIF file)]


Substrate Specificity: Glycolipids (Table VI)

All three isoforms cleaved the A determinant GalNAcalpha (1right-arrow3)-residue from type 1 chain A-6 and A-7 glycosylceramides yielding the underlying H and Leb structures and from Forssman hapten yielding the underlying globoside. Neither IA nor IB degraded the underlying H or Leb structures further; nor did they degrade GM3. Traces of alpha -fucosidase and sialidase in fraction III-PII resulted in partial degradation of GM3 to LacCer and further cleavage of type 1 chain H-5 and Leb to LcOse4Cer, but there was no cleavage of type 2 chain H-5, suggesting that the alpha -fucosidase acts specifically on alpha -fucosyl-(1right-arrow2)-linkages on beta -galactosyl-(1right-arrow3) (type 1) -residues but not on beta -galactosyl-(1right-arrow4) (type 2) -residues.

Table VI.

Substrate specificities of isoforms IA, IB, and III-PII towards glycolipids of known structure

Incubation for 24 h at 37 °C using 0.5-1.0 µl enzyme (7-88 milliunits) per µg of glycolipid.
 alpha -GalNAcase isoform Glycolipid cleavage

IA Cleaved terminal alpha -GalNAc residues from type 1 chain mono- and difucosylated substrates and from pentaosylceramide without further glycolipid degradation:
              type 1 chain A-6 right-arrow H-5
              type 1 A-7 right-arrow Leb-6
              Forssman right-arrow globoside
              GM3 right-arrow no cleavage
Type 2 chain lactoseries glycolipids were not tested with this preparation.
IB Cleaved terminal alpha -GalNAc residues from type 1 chain mono- and difucosylated substrates, type 2 chain monofucosylated substrate, and from non-fucosylated pentaosylceramide without further glycolipid degradation:
               type 1 A-7 right-arrow Leb-6
               type 1 chain A-6 right-arrow H-5
               type 2 chain A-6 right-arrow H-5
               Forssman right-arrow globoside
               GM3 right-arrow no cleavage
III-PII Cleaved terminal alpha -GalNAc residues from type 1 chain mono- and difucosylated substrates, from type 2 chain monofucosylated substrate, and from non-fucosylated pentaosylceramide (Forssman). Contains traces of alpha -L-fucosidase and sialidase.
     type 1 A-7 right-arrow Leb-6 right-arrow Leb-5 right-arrow LcOse4Cer
     type 1 A-6 right-arrow H-5 right-arrow LcOse4Cer
     type 2 A-6 right-arrow H-5 (no cleavage to nLcOse4Cer)
     Forssman right-arrow globoside
     GM3 right-arrow GM3 + LacCer

Kinetic Analysis (Table VII)

Km and Vmax, of isoforms IA, IB, and III-PII, calculated from Lineweaver-Burk plots of the reaction with p-nitrophenyl-alpha -GalNAc, ranged between 2.2 and 5.8 mM and 78-115 µmol/min/mg protein, respectively.

Table VII.

Properties of the alpha -GalNAcase isoforms

Assayed using p-nitrophenyl-alpha -N-acetylgalactosaminide.
Property IA IB III-PII

Km, mM 2.2 5.8 4.8
Vmax, µmol/min/mg 78 115 97
pH optimum 5.8-6.8 5.8-6.8 5.6-6.1
pH stability range 5.0-9.5 5.0-9.5 4.5-9.5
% remaining after 2 h at 50 °C 8 2 47
Anomalous elution from Sephacryl S-300 No No Yes

Range of pH Activity and pH Stability (Fig. 6, Table VII)

Isoforms IA and IB were active over the range 4.7-8.5. They had identical pH activity curves, with optimum pH = 5.8-6.8 and 70-80% of maximum activity present at pH 7.4. By contrast, in two separate studies the pH activity curve of III-PII was shifted 0.5 pH units more acidic; it was active over the range 4.5 to 8.0, and its pH optimum was 5.6-6.1, with 36% of maximum activity present at pH 7.4. All three isoforms were stable for 4 h at 4 °C over the pH range 5.0-9.5 but were unstable below pH 4.5. Isoform III-PII was slightly more heat resistant than IA or IB (Table VII). At 55 °C the activity of all three isoforms was rapidly lost, but at 50 °C 47% of III-PII activity remained after 120 min compared with <10% of IA and IB. Thermal stability was unaltered by addition of 1 mg/ml bovine serum albumin.


Fig. 6. pH activity curves of isoforms IA, IB, and III-PII with pnp-alpha -GalNAc substrate, expressed as percent of maximum activity. Cumulative values of two studies. In both studies the pH activity curve of isoform III-PII was 0.5 pH unit more acidic. Isoform IA, bullet ; IB: black-square, III-PII; square .
[View Larger Version of this Image (12K GIF file)]


Effect of Added Reagents and Ions (Table VIII)

Addition of 0.1% v/v Triton X-100 to the purified isoforms did not increase their activity as it did with cruder preparations (data not shown). Treatment with 0.1 M EDTA inhibited activity of IB by 95-96%, and the activity of IA by 46% but had no inhibitory effect on III-PII. In a separate study, SDS-PAGE of IB after EDTA treatment revealed no change in protein band number, appearance, or migration rate. Neither 10 mM dithiothreitol nor 10 mM MCE affected activity. Treatment with 10 mM iodoacetamide, N-ethylmaleimide, or p-hydroxymercuribenzoate inhibited isoform III-PII more than IA and IB, and isoform III-PII was also inhibited more by HgCl2 and CuSO4. By contrast, addition of 1 mM MgCl2, MnCl2, NiCl2, ZnCl2, CaCl2, Co(NO3)2, FeSO4, or ferric ammonium citrate nonspecifically enhanced the activity of all three isoforms in the order III-PII > IB > IA, the differences being statistically significant (p < 0.05).

Table VIII.

Effect of additives on activity of purified alpha -GalNAcase isoforms

All incubations were at 37 °C and for 1 h unless specified otherwise.
Additive % of activity without additive
IA IB III-PII

0.1% Triton X-100 0.5 h, 105 0.5 h, 114 0.5 h, 111 
10 mM 2-mercaptoethanol 111 96 106
10 mM dithiothreitol 103 90 113
0.1 M Na2EDTA 2 h, 2 h, 2 h,
55 3.9 123
10 mM iodoacetamide 3 h, 3 h, 3 h,
  1 mM 72 91 91
  10 mM 54 41 9
N-Ethylmaleimide
  1 mM 76 107 31
  10 mM 45 86 12
1 mM p-OH-Hg-benzoate
  1 mM 62 44 3.8
  10 mM 69 27 2.7
1 mM HgCl2
  1 mM 63 50 0
  10 mM 0 1.0 2.6
1 mM CuSO4
  1 mM 18 29 7
  10 mM 0.4 2.6 1.2
Mean (and range) enhancing effect of 106%a 116%a 133 %a
1 mM Ca2+, Co2+, (94-123) (96-134) (105-163)
Fe2+, Fe3+, Mg2+,
Mn2+, Ni2+, Zn2+

a p < 0.05 for the differences in enhancing effect.

Stability During Storage

The activity of each isoform was stable over 25-31 months' storage at 4 °C and pH 6 in ESBA buffer at protein concentrations ranging from 66 to 450 µg/ml, and repeat SDS-PAGE after 24 months showed no change in protein pattern or migration. Freezing, thawing, and lyophilization destroyed activity unless performed in the presence of 1 mg/ml bovine or human serum albumin.


DISCUSSION

R. torques (56), a commensal, nonpathogenic, Gram-positive, nonsporulating anaerobe (57), is one of a subset of Ruminococcus and Bifidobacterium strains averaging 1% of human fecal bacteria (29, 34, 58) that is functionally defined as the major producer of extracellular glycosidases degrading ABH and Lewis blood group active oligosaccharide chains of mucin glycoproteins and cell membrane glycolipids (31, 33, 58-60). The mono- and disaccharides resulting from mucin degradation by their exo- and endoglycosidases are utilized by larger fecal populations that do not degrade these chains (59, 61). Of the five strains characterized to date only the two R. torques strains produce strong blood group A-degrading alpha -GalNAcase activity (58-60). In probable adaptation to the enteric environment, the extracellular alpha -GalNAcase and beta -galactosidase of R. torques resist degradation by pancreatic proteases (61). alpha -GalNAcase in cell-free culture supernatants of R. torques is produced constitutively in the range of 70-190 units/liter and is free of proteinases, hemolysins, or toxins (58). However, as with purification of extracellular glycosidases produced by other Gram-positive bacteria (5, 62-65), separation of alpha -GalNAcase from other glycosidases resisted other attempts until we employed hydrophobic interaction chromatography at high ionic strength, resulting in selective elution of isoforms IA and IB free of sialidase, beta -GlcNAc'ase, and alpha -L-fucosidase. Hydroxyapatite chromatography was a useful next step since glycosidases in the undialyzed eluate fractions adhered to it despite high NaCl concentrations.

Extracellular alpha -GalNAcase produced by R. torques exists in at least three isoforms differing in hydrophobicity, size, and enzymatic properties. Isoform III was the largest and most hydrophobic isoform, accounting for half of the total activity recovered from phenyl-Sepharose. Isoform III resembled isoform IA in having the same N-terminal amino acid sequence, but it differed from IA and IB in having a more acidic pH optimum, greater thermal stability, greater sensitivity to metal ions and alkylating agents, and anomalous retardation during gel filtration on Sephacryl S-300. Anomalous retardation of beta -GlcNAc'ase on derivitized dextran gels has also been observed by us2 and by others (66-68); it has been ascribed to hydrophobic interactions as well as to charge effects (69).

Isoform I, the least hydrophobic form, separated during hydroxyapatite chromatography into two isoforms, IA and IB, which differed in molecular size, N-terminal amino acid sequence, and sensitivity to EDTA. The larger, IB, had more Asp and less Ala than IA. It was inactivated by treatment with EDTA without alteration of the subunit size on SDS-PAGE, and activity was not restored by addition of eight metal cations, alone or in combination. This suggests that one or more chelatable metal cations is an intrinsic part of the tertiary structure of IB whose removal results in irreversible changes in catalysis or conformation (70-72).

The subunit size of isoforms IA, IB, and III, 160-200 kDa, is similar to the 180-355-kDa subunit sizes reported for purified extracellular glycosidases of Streptococcus pneumoniae and C. perfringens (12, 73, 74). Such large subunit sizes may be a property of extracellular glycosidases produced by Gram-positive bacteria in contrast to alpha -GalNAcases from other sources (10, 16-18, 21).

Despite differences in isoform properties, the apparent molecular mass of the native isoforms determined by gel filtration bore a ratio of 1.96:3.09:3.93 to the 135-kDa weight-average apparent molecular mass of native isoform IA, suggesting that a segment of approximately 135 kDa was present as a dimer, trimer, and tetramer in native isoforms IA, IB, and III, respectively. Because the isoforms differ in properties and resistance to disulfide bond cleavage, it is unlikely that noncovalent aggregation or linkage via disulfide bonds account for the putative multimeric structure. A model that could account for the observations is one in which the three respective isoforms consist of 2, 3, and 4 tandem repeats of a 135-kDa segment containing an active site sequence and linked by shorter intervening sequences. Tandem repeats were recently reported by Clarke and coworkers (74) in the 144-kDa subunit of S. pneumoniae beta -GlcNAc'ase (74). This contained two tandem repeats of a 335-amino acid sequence which itself contained a highly conserved 30-amino acid sequence that was likely to be part of the active enzymatic site. The model proposed for the alpha -GalNAcase isoforms would need to account for the different N-terminal sequence and EDTA sensitivity of isoform IB as well as its slightly different amino acid composition. The overall similarities of isoform IB with the other isoforms suggests that it is not the product of a separate gene. A stronger possibility is that the isoforms are derived by post-translational proteolytic processing of a single gene precursor polypeptide in which the dimeric and tetrameric isoforms IA and III are cleaved by the same linkage-specific endopeptidase, whereas the trimeric isoform IB is cleaved at a different site by a second endopeptidase, leading to its different N-terminal sequence and properties. This is analogous to the observation (75) that the heterodimeric alpha  and beta  subunits of Escherichia coli acylase arise by separate, highly specific cleavages from a single large precursor polypeptide during post-translational processing.

The observation that the N-terminal amino acid sequence of alpha -GalNAcase isoforms IA and III of R. torques shares homologies with the N-terminal sequence of sialidase isoforms of B. fragilis is of biological interest since both species share the same human enteric habitat at roughly similar fecal population densities (76), yet differ widely in phenotype and phylogeny. The possibility of a common origin during evolution of these microbial hydrolases is an intriguing question that may be answered when their complete structures are determined and compared.


FOOTNOTES

*   This work was supported by the Office of Research and Development, Medical Research Service, Department of Veterans Affairs, and by Grant RO1-HL45659 from the National Institutes of Health, and by Grant 8266 from the Swedish Medical Research Council (to G. L.). Services of the Molecular Biology Core Laboratory of Case Western Reserve University were supported in part by National Institutes of Health Grant P30 CA43703.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
   To whom correspondence should be addressed: VA Medical Center 541/111E(W), 10701 East Blvd., Cleveland, OH 44106-1702. Tel.: 216-791-3800 (Ext. 5253); Fax: 216-231-3447.
1   The abbreviations used are: alpha -GalNAcase, alpha -N-acetylgalactosaminidase; ESB, enzyme separation buffer; CV, coefficient of variation; EAB, enzyme assay buffer; fucosidase, alpha -L-fucosidase; beta -Galase, beta -galactosidase; beta -GlcNAcase, beta -N-acetylglucosaminidase; MCE, 2-mercaptoethanol; MHIC, minimal hemagglutination inhibiting concentration; PAGE, polyacrylamide gel electrophoresis; pNP-, p-nitrophenyl; beta -GalNAcase, beta -N-acetylgalactosaminidase; endo-alpha -GalNAcase, endo-alpha -N-acetylgalactosaminidase.
2   L. C. Hoskins and E. T. Boulding, unpublished observations.

Acknowledgments

We thank Jens Cavallius, Joyce Jenthoft, and William Merrick of the Department of Biochemistry for many helpful suggestions and for running the BLAST search of the protein data base.


REFERENCES

  1. Hoskins, L. C., Larson, G., and Naff, G. B. (1995) Transfusion 35, 813-821 [Medline] [Order article via Infotrieve]
  2. Lenny, L. L., Hurst, R., Goldstein, J., and Galbraith, R. A. (1994) Transfusion 34, 209-214 [CrossRef][Medline] [Order article via Infotrieve]
  3. Lenny, L. L., Hurst, R., Goldstein, J., Benjamin, L. J., and Jones, R. L. (1991) Blood 77, 1383-1388 [Abstract]
  4. Goldstein, J., Siviglia, G., Hurst, R., Lenny, L. L., and Reich, L. (1982) Science 215, 168-170 [Medline] [Order article via Infotrieve]
  5. Levy, G. N., and Aminoff, D. (1980) J. Biol. Chem. 255, 11737-11742 [Abstract/Free Full Text]
  6. Bell, W. C., Pomato, N., and Aminoff, D. (1978) Carbohydr. Res. 61, 447-455 [CrossRef][Medline] [Order article via Infotrieve]
  7. Furukawa, K., and Aminoff, D. (1970) in Blood and Tissue Antigens (Aminoff, D., ed), pp. 415-426, Academic Press, New York
  8. Goldstein, J. (1983) in Progress in Clinical Research (Brewer, G. J., ed), Vol. 65, pp. 139-157, Alan R. Liss, New York
  9. Goldstein, J. (1989) Transfus. Med. Rev. 3, 206-212 [Medline] [Order article via Infotrieve]
  10. Hata, J., Dhar, M., Mitra, M., Harmata, M., Haibach, F., Sun, P., and Smith, D. (1992) Biochem. Int. 28, 77-86 [Medline] [Order article via Infotrieve]
  11. Huang, C. C., and Aminoff, D. (1974) Biochim. Biophys. Acta 371, 462-469 [Medline] [Order article via Infotrieve]
  12. Aminoff, D., and Furukawa, K. (1970) J. Biol. Chem. 245, 1659-1669 [Abstract/Free Full Text]
  13. Macfarlane, G. T., Allison, C., Gibson, S. A. W., and Cummings, J. H. (1988) J. Appl. Bacteriol. 64, 37-46 [Medline] [Order article via Infotrieve]
  14. Hutton, D. A., Pearson, J. P., Allen, A., and Foster, S. N. E. (1990) Clin. Sci. (Lond.) 78, 265-271 [Medline] [Order article via Infotrieve]
  15. Hoskins, L. C., and Boulding, E. T. (1976) J. Clin. Invest. 57, 63-73 [Medline] [Order article via Infotrieve]
  16. Nakagawa, H., Asakawa, M., and Enomoto, N. (1987) J. Biochem. (Tokyo) 101, 855-862 [Abstract]
  17. Itoh, T., and Uda, Y. (1984) J. Biochem. (Tokyo) 95, 959-970 [Abstract]
  18. Sung, S.-S. J., and Sweeley, C. C. (1980) J. Biol. Chem. 255, 6589-6594 [Free Full Text]
  19. Dean, K. J., and Sweeley, C. C. (1979) J. Biol. Chem. 254, 10001-10005 [Medline] [Order article via Infotrieve]
  20. Wiessmann, B., and Hinrichsen, D. (1969) Biochemistry 8, 2034-2043 [Medline] [Order article via Infotrieve]
  21. Kadowaki, S., Ueda, T., Yamamoto, K., Kumagai, H., and Tochikura, T. (1989) Agric. Biol. Chem. 53, 111-120
  22. McDonald, M. J., and Bahl, O. P. (1972) Methods Enzymol. 28, 734-738
  23. Uda, Y., Li, S.-C., Li, Y.-T., and McKibbins, J. M. (1977) J. Biol. Chem. 252, 5194-5200 [Medline] [Order article via Infotrieve]
  24. Yamada, M., Ikeda, K., and Egami, F. (1973) J. Biochem. (Tokyo) 73, 69-76 [Medline] [Order article via Infotrieve]
  25. Muramatsu, T. (1968) J. Biochem. (Tokyo) 64, 521-531 [Medline] [Order article via Infotrieve]
  26. Tuppy, H., and Staudenbauer, W. L. (1966) Biochemistry 5, 1742-1747 [Medline] [Order article via Infotrieve]
  27. Howe, C., and Kabat, E. A. (1953) J. Am. Chem. Soc. 75, 5542-5547
  28. Yagi, F., Eckhardt, A. E., and Goldstein, I. J. (1990) Arch. Biochem. Biophys. 280, 61-67 [Medline] [Order article via Infotrieve]
  29. Miller, R. S., and Hoskins, L. C. (1981) Gastroenterology 81, 759-765 [Medline] [Order article via Infotrieve]
  30. Karlsson, K.-A., and Larson, G. (1981) J. Biol. Chem. 256, 3512-3524 [Abstract/Free Full Text]
  31. Larson, G. L., Falk, P., and Hoskins, L. C. (1988) J. Biol. Chem. 263, 10790-10798 [Abstract/Free Full Text]
  32. McKibben, J. M. (1969) Biochemistry 8, 679-685 [Medline] [Order article via Infotrieve]
  33. Falk, P., Hoskins, L. C., and Larson, G. L. (1990) J. Biochem. (Tokyo) 108, 466-474 [Abstract]
  34. Hoskins, L. C., and Boulding, E. T. (1981) J. Clin. Invest. 67, 163-172 [Medline] [Order article via Infotrieve]
  35. Finch, P. R., Yuen, R., Schacter, H., and Moscarello, M. A. (1969) Anal. Biochem. 31, 296-305
  36. Mokrasch, L. C. (1954) J. Biol. Chem. 208, 55-59 [Free Full Text]
  37. Reissig, J. E., Strominger, J. L., and Leloir, L. F. (1955) J. Biol. Chem. 217, 959-966 [Free Full Text]
  38. Fewster, M. E., Burns, B. J., and Mead, J. F. (1969) J. Chromatogr. 43, 120-126 [CrossRef][Medline] [Order article via Infotrieve]
  39. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. (1951) J. Biol. Chem. 193, 265-275 [Free Full Text]
  40. Böhlen, P., Stein, S., Dairman, W., and Udenfriend, S. (1973) Arch. Biochem. Biophys. 155, 213-220 [Medline] [Order article via Infotrieve]
  41. Maizel, J. V. (1971) Methods Virol. 5, 179-246
  42. Sigma Chemical Co. (1982) SDS Molecular Weight Markers. Technical Bulletin No. MWS-877, St. Louis, MO
  43. Weber, K., and Osborn, M. (1975) in The Proteins (Neurath, H., and Hill, R. L., eds), pp. 179-223, Academic Press, New York
  44. Garfin, D. E. (1990) Methods Enzymol. 182, 425-441 [Medline] [Order article via Infotrieve]
  45. Laemmli, U. K. (1970) Nature 227, 680-685 [Medline] [Order article via Infotrieve]
  46. Zacharius, R. M., Zell, T. E., Morrison, J. H., and Woodlock, J. J. (1969) Anal. Biochem. 30, 148-152 [Medline] [Order article via Infotrieve]
  47. Andrews, P. (1964) Biochem. J. 91, 222-233 [Medline] [Order article via Infotrieve]
  48. Sigma Chemical Co. (1986) Nondenatured Protein Molecular Weight Marker Kit. Technical Bulletin No. MKR-137, St. Louis, MO
  49. Bryan, J. K. (1977) Anal. Biochem. 78, 513-519 [Medline] [Order article via Infotrieve]
  50. Ozols, J. (1990) Methods Enzymol. 182, 587-601 [Medline] [Order article via Infotrieve]
  51. Matsudaira, P. (1990) Methods Enzymol. 182, 602-613 [Medline] [Order article via Infotrieve]
  52. Siegel, S. (1956) Nonparametric Statistics for the Behavioral Sciences, McGraw-Hill Inc., New York
  53. Dean, K. J., and Sweeley, C. C. (1979) J. Biol. Chem. 254, 10006-10010 [Medline] [Order article via Infotrieve]
  54. Altschul, S. E., Gish, W., Miller, W., Myers, E. W., and Lipman, D. J. (1990) J. Mol. Biol. 215, 403-410 [CrossRef][Medline] [Order article via Infotrieve]
  55. Tanaka, H., Ito, F., and Iwasaki, T. (1994) J. Biochem. (Tokyo) 115, 318-321 [Abstract]
  56. Holdeman, L. V., and Moore, W. E. C. (1974) Int. J. Syst. Bacteriol. 24, 260-277
  57. Moore, W. E. C., and Holdeman, L. V. (1974) Appl. Environ. Microbiol. 27, 961-979
  58. Hoskins, L. C., Agustines, M., McKee, W. B., Boulding, E. T., Kriaris, M., and Niedermeyer, G. (1985) J. Clin. Invest. 75, 944-953 [Medline] [Order article via Infotrieve]
  59. Hoskins, L. C., Boulding, E. T., Gerken, T. A., Harouny, V. R., and Kriaris, M. (1992) Microb. Ecol. Health Dis. 5, 193-207
  60. Falk, P., Hoskins, L. C., and Larson, G. L. (1991) Biochim. Biophys. Acta 1084, 139-148 [Medline] [Order article via Infotrieve]
  61. Hoskins, L. C. (1993) Eur. J. Gastroenterol. Hepatol. 5, 205-213
  62. McGuire, E. J., Chipowski, S., and Roseman, S. (1972) Methods Enzymol. 28, 755-763
  63. Huang, C. C., and Aminoff, D. (1972) J. Biol. Chem. 247, 6737-6742 [Abstract/Free Full Text]
  64. Ortiz, J. M., Gillespie, J. B., and Berkeley, R. C. W. (1972) Biochim. Biophys. Acta 289, 174-186 [Medline] [Order article via Infotrieve]
  65. Brown, W. C., Fraser, D. K., and Young, F. E. (1970) Biochim. Biophys. Acta 198, 308-315 [Medline] [Order article via Infotrieve]
  66. Overdijk, B., van der Kroef, W. M., Veltkamp, W. A., and Hooghwinkel, G. J. (1975) Biochem. J. 151, 257-261 [Medline] [Order article via Infotrieve]
  67. Braidman, I., Carroll, M., Dance, N., and Robinson, D. (1974) Biochem. J. 143, 295-301 [Medline] [Order article via Infotrieve]
  68. Braidman, I., Carroll, M., Dance, N., Robinson, D., Poenaru, L., Weber, A., Dreyfus, J. C., Overdijk, B., and Hooghwinkel, G. J. (1974) FEBS Lett. 41, 181-184 [CrossRef][Medline] [Order article via Infotrieve]
  69. Johansson, B.-L., and Gustavsson, J. (1988) J. Chromatogr. 457, 205-213 [CrossRef][Medline] [Order article via Infotrieve]
  70. Vallee, B. L., and Auld, D. S. (1993) Biochemistry 32, 6493-6500 [Medline] [Order article via Infotrieve]
  71. Vallee, B. L., and Auld, D. S. (1992) Faraday Discuss. Chem. Soc. 93, 47-65
  72. Coleman, J. E. (1992) Annu. Rev. Biophys. Biomol. Struct. 21, 441-483 [CrossRef][Medline] [Order article via Infotrieve]
  73. Glasgow, L. R., Paulson, J. C., and Hill, R. L. (1977) J. Biol. Chem. 252, 8615-8623 [Medline] [Order article via Infotrieve]
  74. Clarke, V. A., Platt, N., and Butters, T. D. (1995) J. Biol. Chem. 270, 8805-8814 [Abstract/Free Full Text]
  75. Sizmann, D., Keilmann, C., and Bock, A. (1990) Eur. J. Biochem. 192, 143-151 [Abstract]
  76. Holdeman, L. V., Good, I. J., and Moore, W. E. C. (1976) Appl. Environ. Microbiol. 31, 359-375 [Medline] [Order article via Infotrieve]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.